CoreMedic

Executive Summary

CoreMedic GmbH is a German medical device company developing ChordArt, a transcatheter mitral valve repair (TMVr) system for primary mitral regurgitation (MR). Spin-out from Bern, Switzerland, the company is based in Radolfzell, Germany's medtech cluster. ChordArt aims to be a first-line, catheter-based alternative to surgical repair, addressing the large unmet need in MR treatment. The system is designed to simplify the procedure and improve outcomes, potentially competing with established TMVr devices like MitraClip. CoreMedic's technology is in the preclinical or early clinical stage, with no disclosed funding or regulatory milestones. The company operates in the rapidly growing TMVr market, projected to exceed $3 billion by 2030. Success depends on demonstrating safety and efficacy in clinical trials, securing regulatory approvals, and obtaining reimbursement. With limited public information, CoreMedic's potential is significant but speculative.

Upcoming Catalysts (preview)

• Q4 2026First-in-Human Study Initiation60% success
• Q2 2027CE Mark Application Submission40% success
• Q3 2026Series B Financing Round50% success